At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 60 enrolled
Drug / intervention
Herpes zoster vaccine GSK1437173Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older
In Brief
A Phase 3 clinical trial evaluating Herpes zoster vaccine GSK1437173A for Herpes Zoster. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of GSK Biologicals' Herpes Zoster (HZ) vaccine (GSK 1437173A) when administered subcutaneously (SC) as compared to intramuscularly (IM) to people 50 years of age and older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartJun 2013
Primary CompletionOct 2013
Study CompletionNov 2014
TodayJul 2026
First PostedJan 28, 2013
Enrollment StartJun 17, 2013
Primary CompletionOct 10, 2013
Study CompletionNov 11, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.4 years ago
Interventions
Herpes zoster vaccine GSK1437173Abiological
HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.